TGTX · TG Therapeutics, Inc. · Stock research

Current Thesis

The August print resolved the binary this coverage was pointed at, and it resolved in two directions at once. On 2026-08-03 TG Therapeutics reported Q2 2026 total global revenue of $240.3M against roughly $229.7M consensus, US BRIUMVI net product revenue of $227.7M (+64% YoY, versus $194.8M in Q1 2026), and raised FY2026 total global revenue guidance to approximately $950M with US BRIUMVI net product revenue to $890–905M, up from $885–900M. That is the third upward revision this year against the February guide of $825–850M. The market sold it: EPS printed $0.05 against roughly $0.33 expected, and Yahoo Finance recorded a 15.9% one-day decline after the release. The gap between the top line and the bottom line is disclosed and largely mechanical — R&D of $95.3M included about $54.6M of subcutaneous manufacturing cost, on top of SG&A of $82.1M and cost of revenue of $41.2M. JPMorgan maintained Overweight and raised its target to $72 on 2026-08-07, after the selloff. Price closed at $48.74 on 2026-08-14, 17.5% below the $59.06 52-week high, still +23.4% over three months. The narrative leg an investor is buying at this level is no longer a catalyst

Bullish and bearish views on TG Therapeutics, Inc.

The model's bull view on TG Therapeutics, Inc. (TGTX), in brief: US BRIUMVI net $227.7M in Q2 2026, +64% YoY (2026-08-03 release), sequential acceleration from $194.8M in Q1 2026 — the run-rate, not the guide, is what has been compounding. The bear view: A beat-and-raise was sold 15.9% in a day (2026-08-03 print). Both cases follow in full.

Bull Case

• US BRIUMVI net $227.7M in Q2 2026, +64% YoY (2026-08-03 release), sequential acceleration from $194.8M in Q1 2026 — the run-rate, not the guide, is what has been compounding.
• Third FY2026 raise in six months: ~$950M total global revenue and $890–905M US BRIUMVI net (2026-08-03), against $825–850M US guided in February 2026. Management has revised up at every print this year.

• Balance sheet does not require the equity market: cash, cash equivalents and investment securities of $612.3M at 2026-06-30, with the company reporting net income of $7.8M in the quarter.
• The EPS miss is identifiable spend, not deteriorating economics: cost of revenue $41.2M against $235.8M of product revenue; the R&D line carried ~$54.6M of subcutaneous manufacturing build.
• Sell-side raised into the drawdown: JPMorgan Overweight, target to $72 (2026-08-07); HC Wainwright Buy at $77 (2026-07-13). Both sit far above the 2026-08-14 close of $48.74.
• Two unfinished second acts: subcutaneous BRIUMVI Phase 3 topline guided to year-end 2026 or early 2027, and the ~120-patient MG Phase 2 (efgartigimod induction → BRIUMVI maintenance) initiated 2026-06-09.

Bear Case

• A beat-and-raise was sold 15.9% in a day (2026-08-03 print). Whatever the marginal bid was paying for in the run to $59.06, another revenue upgrade did not renew it.
• Two consecutive quarters of spend outrunning the top line are guided: FY2026 R&D plus SG&A ex non-cash compensation of $350–400M, plus approximately $100M of additional manufacturing and startup costs. EPS leverage is deferred until the subcutaneous build rolls off.
• The next company-controlled binary is months away. Subcutaneous Phase 3 topline is year-end 2026 or early 2027; full ENHANCE results are only guided to "2026". Nothing dated bridges August to late October.
• Target dispersion is wide and the low end is materially below spot. Alongside the $72 and $77 targets, aggregators still carry Street numbers well under the current price; the median has not converged on the bulls.
• MG rests on n=11. The 2026-06-09 Phase 1 was open-label with 11 patients (82% hitting MG-ADL minimal clinically important difference by Week 24, 4.6-point mean improvement, 30-day median time to response). The controlled test has no guided readout date.
• Single-product concentration: $227.7M of $240.3M Q2 revenue is one US product in one indication.

Setup & Price Structure

The narrative is maturing. The narrative still works on the numbers — the 2026-08-03 guide raise and the 2026-08-07 JPMorgan target lift to $72 are both fresh — but flow has moderated sharply from the June regime. Dating it: RSI(14) ran to a blow-off near 94 in mid-June on the 2026-06-09 MG data, sat in the high-70s through late July, and printed 30.6 on 2026-08-14. Price is 17.5% off the $59.06 high while still +23.4% on three months, so the June re-rate is intact and the momentum leg on top of it is not.

Structure: the $46–48 zone is the shelf that matters. It was the old median-target area the stock broke through in June, retested through July, and now sits directly above at $48.74. Below it, the reference is the pre-MG-print range near $42, where the stock traded on 2026-06-09. A weekly close under $46 would put price back inside that range and remove the June breakout from the chart.

Positioning observables, stated as observables: the most recent FINRA settlement to surface is 2026-06-15, showing about 30M shares short, 19.73% of shares outstanding and 12.12 days to cover — that is a pre-print snapshot and says nothing about whether the base covered into the August decline. The elevated-RSI screening coverage that clustered around this name in mid-June (Benzinga, 2026-06-15, TGTX RSI 79.8) has not been replaced by equivalent attention at RSI 30.6. There is no earnings date inside the next 30 days. No insider transaction or equity issuance dated after the print surfaced in this review; the company reported $612.3M of cash and investments at quarter end, which removes the usual small-cap biotech financing pressure.

Catalyst Calendar (next 30 days)

• No company-scheduled catalyst falls inside 2026-08-16 → 2026-09-15. The 2026-08-03 Q2 print has passed; the next scheduled disclosure is the Q3 report, ~2026-11-03 (est.).
• ~2026-08-26 (est.) — FINRA short-interest report covering the 2026-08-14 settlement: the first read on whether the ~19.7% short base covered into the post-print decline.
• 2026-10-21 to 2026-10-23 — Joint ACTRIMS–ECTRIMS meeting (MSToronto 2026), the plausible venue for the full ENHANCE dataset the company said would be presented in 2026, and for the full MG Phase 1 data.
• ~2026-12-31 (est.) — subcutaneous BRIUMVI Phase 3 topline, guided year-end 2026 or early 2027.

What Would Change Our Mind

The structure carrying this read is the $46–48 shelf and the pre-MG range beneath it. Losing that shelf on a weekly close below $46 returns price to where it traded before the 2026-06-09 MG topline and negates the entire June re-rate, at which point the story is a growth franchise being priced on spend rather than on revenue. Second condition: a Q3 print (~2026-11-03, est.) that does not lift the $890–905M US BRIUMVI guide, or that shows US net product revenue below the $227.7M Q2 level, would break the sequential-acceleration claim that is the actual thesis. Third: if the theme flips to saturated — another beat-and-raise met with a negative one-day reaction, with no new participation — the fundamental upgrades stop mattering to price. On the other side, evidence that would strengthen the read is narrow and specific: a FINRA settlement showing the short base intact through the decline, plus a weekly close back above $53 reclaiming the July consolidation range.

Correlation Notes

• Direct read-across to the MS franchise incumbents — Roche (Ocrevus, including its subcutaneous format) and Novartis (Kesimpta) — since the subcutaneous BRIUMVI Phase 3 is explicitly a convenience-parity attempt against at-home dosing. Competitive disclosures from either on SC MS share are the relevant third-party datapoint.
• Argenx is on both sides: efgartigimod is the induction agent in the MG Phase 2 initiated 2026-06-09, and argenx's franchise is the incumbent this program is trying to displace on maintenance burden.
• Beta to XBI/IBB is real but the linkage is loosening as revenue scales — this is a profitable, cash-generating name ($7.8M net income, $612.3M cash at 2026-06-30) rather than a rate-duration clinical asset. That characterisation is an inference from the financials, not a measured correlation.
• BRIUMVI is physician-administered, so US drug-pricing and reimbursement headlines transmit through the Part B channel rather than the retail-pharmacy channel that dominates sector coverage.